Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies

“Ovarian Cancer Therapeutics in Major Developed Markets to 2020 Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies”, The current Ovarian cancer therapeutics market is dominated by the use of generics – predominately carboplatin and paclitaxel, which are used in combination for the treatment of platinum-sensitive disease (both first-line and recurrent). As a result the global market is expected not be driven by new drug approvals, but primarily inflation, and the increase in the prevalence of pancreatic cancer. Global market revenues are forecast to rise at a limited CAGR of 3.4% to $1.9billion in 2020.